Details:

Personal Author:
Bridges, Carolyn B. ; Cox, Nancy (Nancy J.) ; Fukuda, Keiji ; Harper, Scott A. ;
Bridges, Carolyn B. ; Cox, Nancy (Nancy J.) ; Fukuda, Keiji ; Harper, Scott A. ; Less -
Corporate Authors:
United States, Advisory Committee on Immunization Practices. ; National Center for Infectious Diseases (U.S.), Division of Viral and Rickettsial Diseases. ; National Immunization Program (Centers for Disease Control and Prevention), Epidemiology and Surveillance Division. ;
United States, Advisory Committee on Immunization Practices. ; National Center for Infectious Diseases (U.S.), Division of Viral and Rickettsial Diseases. ; National Immunization Program (Centers for Disease Control and Prevention), Epidemiology and Surveillance Division. ; Less -
Description:
This report summarizes recommendations by the Advisory Committee on Immunization Practices (ACIP) for using intranasally administered, trivalent, cold-adapted, live, attenuated influenza vaccine (LAIV), which was approved for use in the United States on June 17, 2003 (FluMist trade mark, produced by MedImmune, Inc., Gaithersburg, Maryland). LAIV is currently approved for use among healthy persons (i.e., those not at high risk for complications from influenza infection) aged 5-49 years. This report includes information regarding 1) vaccine composition and mechanisms of action; 2) comparison between LAIV and trivalent inactivated influenza vaccine; 3) effectiveness and safety of LAIV; 4) transmission and stability of LAIV viruses; 5) recommendations and contraindications for using LAIV; and 6) dosage and administration of LAIV. This report supplements the 2003 ACIP recommendations regarding prevention and control of influenza (CDC. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2003;52[No. RR-8]:1-36.)
Content Notes:
prepared by Scott A. Harper, Keiji Fukuda, Nancy J. Cox, Carolyn B. Bridges. The material is this report originated in the National Center for Infectious Diseases, Division of Viral and Rickettsial Diseases; and the National Immunization Program, Epidemiology and Surveillance Division. Includes bibliographical references and index (p. 7-8). 1/13/2014 JCSmith
Subject:
[+]
Administration & Dosage
Adverse Effects
Contraindications
Influenza, Human
Influenza Vaccines
Prevention & Control
Standards
Vaccination
Vaccines, Attenuated
Influenza, Human/Prevention & Control
Influenza Vaccines/Administration & Dosage
Influenza Vaccines/Adverse Effects
Influenza Vaccines/Contraindications
Vaccination/Standards

Series:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 52, no. RR-13;
Pubmed ID:
14557799
Document Type:
Journal Issue ;
Genre:
Practice Guideline ;
Collection(s):
Guidelines and Recommendations
Stephen B. Thacker CDC Library collection
Advisory Committee on Immunization Practices (ACIP)
Main Document Checksum:
[+]
urn:sha256:98a2dbd5f550326e670ffdfd9174135574d663f4b813ff1fbd9fcb7d60b0728c
File Type:

Supporting Files

• No Additional Files

More +